JAZZ On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

Fourth Floor

One Burlington Road

Dublin, 4


Phone: 353 1 634 7800

Fax: 353 1 634 7850

g in growth opportunities such as new treatment indications; acquiring clinically meaningful and differentiated products that are on the market or product candidates that are in late-stage development; and pursuing targeted development of post-discovery differentiated product candidates. Research and Development The company’s development projects include clinical development of new product candidates, activities related to line extensions for existing products and the generation of additional clinical data for existing products. These projects are concentrated in the company’s sleep and hematology/oncology therapeutic areas. In the sleep area, the company has ongoing and planned development programs for Xyrem and certain product candidates. JZP-110 Phase 3 Clinical Trials. JZP-110 is a late-stage investigational compound being developed for potential treatment of EDS in patients with narcolepsy and EDS in patients with OSA. The company is conducting one Phase 3 clinical trial in patients with EDS associated with narcolepsy and two Phase 3 clinical trials in patients with EDS associated with OSA. Other Activities: The company is also exploring additional potential indications for JZP-110. Xyrem Phase 3 Clinical Trial of Xyrem in Children and Adolescents: The company initiated a Phase 3 clinical trial to assess the safety and efficacy of Xyrem in children and adolescents aged 7to 17 who have narcolepsy with cataplexy. Other Activities: The company is also pursuing other activities related to the potential development of options for narcolepsy patients that would provide clinically meaningful improvements compared to Xyrem, including once-nightly dosing. In the hematology and oncology area, the company has ongoing and planned development activities. Defibrotide Planned Phase 3 Clinical Trial: The company is preparing to commence a clinical trial to evaluate the safety and efficacy of defibrotide for the prevention of VOD in high-risk patients. Other Activities: The company is exploring additional potential indications for defibrotide and assessing the potential to pursue regulatory approval of defibrotide in additional countries. Erwinaze: The company is pursuing activities related to the potential development of an effective and well-tolerated long-acting recombinant crisantaspase. It is also assessing the potential to pursue regulatory approval of Erwinaze in additional countries. For the year ended December 31, 2015, the company recorded research and development expenses of $135.3 million. Sales and Marketing The company has commercial operations primarily in the U.S. and Europe. In the U.S., its products are marketed through its commercial teams, including sales professionals who promote Xyrem, Erwinaze and Prialt directly to physicians in specialties appropriate for each product. Outside of the U.S., its hematology and oncology sales force has hematology field specialists responsible for promoting Erwinase and Defitelio in approved markets where the company commercializes these products. The company’s commercial activities include marketing-related services, distribution services and commercial support services. Customers and Geographic Areas In the United States, the company’s primary marketed product Xyrem is sold to one specialty pharmacy, Express Scripts, which ships Xyrem directly to patients. Erwinaze is sold through an exclusive wholesaler and distributor, McKesson Corporation. Outside of the U.S., the company distributes Erwinase through Durbin PLC, a U.K.-based wholesaler and distributor, to hospitals and local wholesalers in Europe where it markets Erwinase directly and, in markets where it does not market Erwinase directly, to local distributors and wholesalers in Europe and elsewhere in the world. The company distributes Defitelio to the European countries where the product has been launched commercially primarily through IDIS Limited (IDIS), a U.K.-based distributor. It also works with IDIS and various local distributors in Europe and elsewhere in the world to distribute defibrotide on a named patient basis. Suppliers The company has an agree


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JAZZ.
View Industry Companies

Industry Analysis


Industry Average

Valuation JAZZ Industry Range
Price/Earnings 26.8x
Price/Sales 6.4x
Price/Book 5.3x
Price/Cash Flow 20.0x
TEV/Sales 4.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.